Ipilimumab/nivolumabImmune-mediated colitis : case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1885卷 / 1期

关键词：

D O I：

10.1007/s40278-021-07040-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：281 / 281

相关论文

共 50 条

[31] Ipilimumab/nivolumabImmune-mediated enterocolitis, pancreatitis and lack of efficacy: 2 case reports
Reactions Weekly, 2024, 2024 (1) : 242 - 242
[32] NivolumabImmune-mediated lichen ruber pemphigoides: case report
Reactions Weekly, 2018, 1733 (1) : 260 - 260
[33] NivolumabImmune-mediated pneumonia and lack of efficacy: case report
Reactions Weekly, 2025, 2041 (1) : 309 - 309
[34] NivolumabImmune-mediated colitis, enteritis and neobladder pouchitis
Reactions Weekly, 2024, 2015 (1) : 339 - 339
[35] Ipilimumab/nivolumabImmune mediated hepatitis: case report
Reactions Weekly, 2019, 1757 (1) : 176 - 176
[36] Ipilimumab/nivolumabImmune-related colitis: case report
Reactions Weekly, 2023, 1961 (1) : 236 - 236
[37] Ipilimumab/nivolumabImmune mediated hepatitis: case report
Reactions Weekly, 2021, 1869 (1) : 193 - 193
[38] NivolumabImmune-mediated pericarditis, pericardial tamponade and thyroiditis: case report
Reactions Weekly, 2018, 1720 (1) : 194 - 194
[39] Ipilimumab/nivolumabImmune-related-diarrhea and colitis: case report
Reactions Weekly, 2024, 2036 (1) : 232 - 232
[40] Ipilimumab/nivolumabImmune-mediated lichenoid drug eruption-sparing scar burns
Reactions Weekly, 2024, 2001 (1) : 183 - 183

← 1 2 3 4 5 →